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Introduction: TGFBR1*6A, a functionally polymorphic allele in the
transforming growth factor  receptor 1 gene (TGFBR1), has been
hypothesized to increase risk of various cancers. However, little has
been documented about connection of this variant with lung cancer.
Methods: In an attempt to explore whether the TGFBR1*6A is
associated with lung cancer, we performed genotyping followed
by sequencing in 252 patients with lung cancer and 250 healthy
controls.
Results: The frequency for the heterozygote 9A/6A is 13.9% in
cases compared with 12.4% in controls, and the odds ratio is 1.14
(95% confidence interval: 0.68–1.91), which is not statistically
significant (p  0.62), suggesting that TGFBR1*6A could not be a
cancer susceptibility factor for Chinese patients with lung cancer.
Conclusions: We have no evidence to support the hypothesis that
TGFBR1*6A is associated with lung cancer.
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(J Thorac Oncol. 2007;2: 657–659)
There is compelling evidence indicating that TGFBR1*6Ais a functionally polymorphism and plays an important
role in initiation and progression of cancer.1,2 TGFBR1*6A
may function as a tumor susceptibility allele by switching
transforming growth factor (TGF-) mediated inhibition of
growth into stimulation of growth and also seems to be
somatically acquired by primary tumors and metastases.2
More recently, two meta-analyses for association between
TGFBR1*6A and cancer risk have shown that TGFBR1*6A is
emerging as a high-frequency, low-penetrance tumor suscep-
tibility allele in the development of breast, ovarian, and
colorectal cancer as well as hematologic malignancies,3,4
suggesting that this polymorphic allele could be also be
associated with an increased risk of other types of cancers
including lung cancer. However, no report on whether
TGFBR1*6A could increase the risk of lung cancer has been
found so far. To address this hypothesis, we carried out an
unrelated case-control study in the southeast area of China to
explore whether the TGFBR1*6A is associated with lung
cancer.
METHODS
All the cases and controls were from the same geo-
graphic region, the southeast area of China, and matched by
age and ethnicity (Table 1). Case blood samples were col-
lected after informed consent was provided by 252 patients
with a diagnosis of lung cancer in about 2005 (Table 2). This
study was approved by the Institutional Review Board of
Suzhou University. These 252 specimens include histologi-
cally defined adenocarcinoma (n  108), squamous cell
carcinoma (n  82), adenosquamous carcinoma (n  23),
large cell carcinoma (n  19), and small cell lung cancer
(n  20). Most of these patients had not received radiother-
apy or chemotherapy before blood sampling. In addition to
the case samples, a total of 250 blood samples were also
collected from subjects with no history of cancer to be used
as controls. Genomic DNA was isolated from the blood
samples according to standard proteinase K digestion and
phenol-chloroform extraction.
Genotyping was performed on blood samples as de-
scribed by Samowitz et al.5 previously. Briefly, 119bp PCR
products were amplified from genomic DNA using the prim-
ers 5=-ccacaggcggtggcggcgggaccatg-3= (forward primer) and
5=-cgtcgcccccgggagcagcgccgc-3= (reverse primer) designed
by Pasche et al.6 Of the two primers, the forward one was
labeled with FAM dye at the 5= end. Following the amplifi-
cation with guanine cytimidine (GC)-rich buffer (TaKaRa
Biotech), polymerase chain reaction (PCR) products were
electrophoresed in a 4% acrylamide gel on ABI 3100 Genetic
Analyzer (Applied Biosystems), and PCR product size was
recognized by means of GeneMapper software. Both
TGFBR1*9A and TGFBR1*6A alleles were further confirmed
by TA clone sequencing.
Unconditional logistic regression was carried out to
assess the association between TGFBR1*6A and lung cancer.
Differences were taken be significant at p 0.05. In addition,
Hardy-Weinberg equilibrium (HWE) for patients and con-
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trols was calculated using the DeFinetti program (https://
ihg.gsf.de/cgi-bin/hw/hwa1.pl).
RESULTS AND DISCUSSION
As illustrated in Figure 1, two genotypes including
9A/9A and 9A/6A were identified in cases and controls. We
found no homozygote for the 6A in both cases and controls,
which could be explained by the fact that the TGFBR186A
allele is not common in populations.7 The observed frequen-
cies for this polymorphism were in agreement with those
expected from the Hardy-Weinberg equilibrium among con-
trols (p  0.67). Table 3 shows the genotype frequencies,
odds ratios (ORs), 95% confidence intervals (CIs), and p
values for association between the TGFBR1*6A and lung
cancer. As shown in Table 3, the frequency for the hetero-
zygote 9A/6A is 13.9% (35/252) in cases compared with
12.4% (31/250) in controls and OR is 1.14 (95% CI: 0.68–
1.91), which is not statistically significant (p  0.62), sug-
gesting that TGFBR1*6A could not be a cancer susceptibility
factor for Chinese patients with lung cancer. In addition,
no association of heterozygote 9A/6A with age, gender,
and smoking history was observed in lung cancer patients
(Table 4).
Although the frequency of the TGFBR1*6A variant has
been reported in lung cancer,1 the case-control analysis regard-
ing this variant remains unclear. Moreover, our previous meta-
analysis of TGFBR1*6A that included 6968 cases with several
types of cancers and 6145 controls showed an overall OR of
1.22 (95% CI: 1.12–1.34) among TGFBR1*6A carriers com-
pared with the wild-type TGFBR1*9A/TGFBR1*9A.4 There-
fore, we hypothesized an association between TGFBR1*6A and
lung cancer. In the present study, we found no association of
TABLE 1. Characteristics of Lung Cancer Patients and
Controls
Cases (n  252),
No. (%)
Controls (n  250),
No. (%) pa
Age, yr 0.229
55 76 (30.2) 89 (35.6)
55 176 (69.8) 161 (64.4)
Sex 0.486
Male 201 (79.8) 192 (76.8)
Female 51 (20.2) 58 (23.2)
Smoking history 0.431
Never 163 (64.7) 171 (68.4)
Ever 89 (35.3) 79 (31.6)
a For 2 test.
TABLE 2. Clinicopathological Features in 252 Lung Cancer
Patients in This Study
Clinicopathological Factors No. (%) of Cases
Tumor size
T1 38 (15.1)
T2 134 (53.2)
T3 57 (22.6)
T4 23 (9.1)
Nodal involvement
N0 131 (52.0)
N1 92 (36.5)
N2 19 (7.5)
N3 10 (4.0)
Metastasis
M0 244 (96.8)
M1 8 (3.2)
Histological types
Adenocarcinoma 108 (42.9)
Squamous cell carcinoma 82 (32.5)
Adenosquamous carcinoma 23 (9.1)
Large cell carcinoma 19 (7.5)
Small cell lung cancer 20 (8.0)
FIGURE 1. Representative electropherograms of the
9A/9A and 6A/9A genotypes. Ineach graph, the scale at
the top shows fragment size; the scale on the left shows
signalamplitude.
TABLE 3. Genotype Frequencies of the TGFBR1 9A/6A
among Cases and Controls and Their Contributions to the
Risk of Lung Cancer
TGFBR1 Genotype
Cases
(n  252)
Controls
(n  250) OR (95% CI) p
9A/9A 217 219 1.00
9A/6A 35 31 1.14 (0.68–1.91) 0.62
6A/6A 0 0
OR, odds ratio; CI, confidence interval.
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TGFBR1*6A with lung cancer in China. To exclude the meth-
odological bias and false-negative results for screening
TGFBR1*6A, we performed TA clone sequencing analysis in
parts of samples to confirm the results from genotyping (Figure
2). Data from sequencing were consistent with those from
genotyping, indicating that genotyping with the method de-
signed previously by Samowitz et al.5 was successful and reli-
able in the present study.
In addition to our null results obtained in lung cancer,
Kaklamani et al.8 did not suggest that the TGFBR1*6A
predisposes to the development of prostate cancer. What is
more, there was no evidence of an association between
TGFBR1*6A and invasive and postmenopausal breast
cancer.7,9 Taken together, the TGFBR1*6A could be a spe-
cific susceptibility allele responsible for certain types of
cancers, such as colorectal cancer.10
In conclusion, we found no evidence to support the
hypothesis that TGFBR1*6A is associated with lung
cancer.
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TABLE 4. Association of TGFBR1 9A/6A with Age, Gender,
and Smoking History of Lung Cancer Patients
9A/9Aa 9A/6Ab pc
Age, yr 0.675
55 67 9
55 150 26
Sex 0.473
Male 171 30
Female 46 5
Smoking history 0.415
Never 143 20
Ever 74 15
a Number of cases with 9A/9A.
b Number of cases with 9A/6A.
c For 2 test.
FIGURE 2. Schematic representation of TA clone sequenc-
ing of the TGFBR1*9A and TGFBR1*6A alleles.
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